Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions.
The HIV-1 envelope glycoprotein (Env) composed of the receptor binding domain gp120 and the fusion protein subunit gp41 catalyzes virus entry and is a major target for therapeutic intervention and for neutralizing antibodies. Env interactions with cellular receptors trigger refolding of gp41, which induces close apposition of viral and cellular membranes leading to membrane fusion. The energy released during refolding is used to overcome the kinetic barrier and drives the fusion reaction. Here, we report the crystal structure at 2 A resolution of the complete extracellular domain of gp41 lacking the fusion peptide and the cystein-linked loop. Both the fusion peptide proximal region (FPPR) and the membrane proximal external region (MPER) form helical extensions from the gp41 six-helical bundle core structure. The lack of regular coiled-coil interactions within FPPR and MPER splay this end of the structure apart while positioning the fusion peptide towards the outside of the six-helical bundle and exposing conserved hydrophobic MPER residues. Unexpectedly, the section of the MPER, which is juxtaposed to the transmembrane region (TMR), bends in a 90 degrees-angle sideward positioning three aromatic side chains per monomer for membrane insertion. We calculate that this structural motif might facilitate the generation of membrane curvature on the viral membrane. The presence of FPPR and MPER increases the melting temperature of gp41 significantly in comparison to the core structure of gp41. Thus, our data indicate that the ordered assembly of FPPR and MPER beyond the core contributes energy to the membrane fusion reaction. Furthermore, we provide the first structural evidence that part of MPER will be membrane inserted within trimeric gp41. We propose that this framework has important implications for membrane bending on the viral membrane, which is required for fusion and could provide a platform for epitope and lipid bilayer recognition for broadly neutralizing gp41 antibodies.
Buzon
Victor
V
Unit of Virus Host Cell Interactions UMI 3265, Université Joseph Fourier-EMBL-CNRS, Grenoble, France.
Natrajan
Ganesh
G
Schibli
David
D
Campelo
Felix
F
Kozlov
Michael M
MM
Weissenhorn
Winfried
W
D057134:Antibodies, Neutralizing / Q000276:immunology; D003461:Crystallography; D000939:Epitopes / Q000737:chemistry; D015483:HIV Antibodies / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000737:chemistry* / Q000276:immunology; D015497:HIV-1 / Q000737:chemistry* / Q000276:immunology; D050576:Membrane Fusion Proteins / Q000737:chemistry* / Q000276:immunology; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D014760:Viral Fusion Proteins / Q000737:chemistry* / Q000276:immunology
D057134:Antibodies, Neutralizing; D000939:Epitopes; D015483:HIV Antibodies; D015700:HIV Envelope Protein gp41; D050576:Membrane Fusion Proteins; D014760:Viral Fusion Proteins; C514787:gp41 protein, Human immunodeficiency virus 1
J Cell Biol. 1998 Jan 26;140(2):315-23
9442107
Nat Struct Mol Biol. 2006 Aug;13(8):740-7
16862157
Science. 2005 Jun 24;308(5730):1906-8
15860590
Nat Struct Mol Biol. 2008 Jul;15(7):675-83
18596814
Annu Rev Biochem. 2003;72:175-207
14527322
Biophys J. 2007 Aug 1;93(3):876-85
17513369
Biophys J. 1998 Sep;75(3):1384-96
9726939
J Virol. 2009 Feb;83(3):1523-31
19019953
FEBS Lett. 2004 Jun 4;567(2-3):183-8
15178320
J Virol. 2009 Sep;83(17):8451-62
19515770
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
15299374
Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7235-40
11404463
J Virol. 2005 Jan;79(2):1252-61
15613352
Nat Rev Microbiol. 2006 Jan;4(1):67-76
16357862
Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
16369096
Biophys J. 2008 Sep;95(5):2325-39
18515373
Curr Opin Immunol. 1997 Aug;9(4):551-62
9287172
Mol Biol Cell. 2003 Mar;14(3):926-38
12631714
Immunity. 2008 Jan;28(1):52-63
18191596
Biochemistry. 2001 Aug 14;40(32):9570-8
11583156
J Virol. 2006 May;80(9):4388-95
16611898
Traffic. 2000 Aug;1(8):622-30
11208150
Nature. 2009 Jul 23;460(7254):525-8
19571812
Cell. 1997 Apr 18;89(2):263-73
9108481
Nat Struct Biol. 1995 Dec;2(12):1075-82
8846219
Biochemistry. 2009 Apr 7;48(13):2915-23
19226163
Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4
7937889
J Virol. 2009 Oct;83(19):10048-57
19625396
J Virol. 1999 Mar;73(3):2469-80
9971832
Nat Struct Mol Biol. 2008 Jul;15(7):690-8
18596815
J Virol. 2004 Oct;78(19):10724-37
15367639
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
15572765
Nature. 1997 May 22;387(6631):426-30
9163431
Nat Struct Biol. 1998 Apr;5(4):276-9
9546217
Adv Virus Res. 2005;64:231-61
16139596
Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54
12393927
Cell. 1998 May 29;93(5):681-4
9630213
J Cell Biol. 2000 Oct 16;151(2):413-23
11038187
Biochemistry. 2008 Jul 1;47(26):6782-92
18540633
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20234-9
19906992
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3739-44
18322015
J Virol. 1999 Jul;73(7):6089-92
10364363
PLoS One. 2010 Jan 20;5(1):e8805
20098712
J Biol Chem. 2001 Jan 12;276(2):1391-7
11027678
EMBO J. 1996 Apr 1;15(7):1507-14
8612573
Cell Mol Life Sci. 2008 Jun;65(11):1716-28
18345480
Curr Opin Struct Biol. 2007 Aug;17(4):427-36
17870467
Immunity. 2005 Feb;22(2):163-73
15723805
Biochim Biophys Acta. 2003 Jul 11;1614(1):36-50
12873764
Biochemistry. 2007 Feb 6;46(5):1398-401
17260969
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
19461840
Science. 2007 May 25;316(5828):1205-8
17478680
J Biol Chem. 2007 Aug 10;282(32):23104-16
17526486